New drug SNP-610 aims to lower liver enzymes in NASH patients
Disease control
Not yet recruiting
This study tests whether the drug SNP-610 can improve liver health in people with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. About 80 adults with high liver enzymes and at least 10% liver fat will receive either SNP-610 or a placebo for 3 months. The mai…
Phase: PHASE2 • Sponsor: Sinew Pharma Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC